EA201900443A1 - Антитело к pd-l1 и его применение - Google Patents

Антитело к pd-l1 и его применение

Info

Publication number
EA201900443A1
EA201900443A1 EA201900443A EA201900443A EA201900443A1 EA 201900443 A1 EA201900443 A1 EA 201900443A1 EA 201900443 A EA201900443 A EA 201900443A EA 201900443 A EA201900443 A EA 201900443A EA 201900443 A1 EA201900443 A1 EA 201900443A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fully human
antibodies
disclosed
affinity
lymphocytes
Prior art date
Application number
EA201900443A
Other languages
English (en)
Russian (ru)
Inventor
Ян Лавровский
Тинг Ксу
Сергей Барбашов
Алексей Репик
Михаил Самсонов
Василий Игнатьев
Шорена Арчуадзе
Original Assignee
Р-Фарм Оверсиз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Р-Фарм Оверсиз Инк. filed Critical Р-Фарм Оверсиз Инк.
Publication of EA201900443A1 publication Critical patent/EA201900443A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
EA201900443A 2017-04-18 2018-04-18 Антитело к pd-l1 и его применение EA201900443A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2017028206 2017-04-18
PCT/US2018/028206 WO2018195226A1 (en) 2017-04-18 2018-04-18 Anti-pd-l1 antibody and use thereof

Publications (1)

Publication Number Publication Date
EA201900443A1 true EA201900443A1 (ru) 2020-03-06

Family

ID=63856823

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201900443A EA201900443A1 (ru) 2017-04-18 2018-04-18 Антитело к pd-l1 и его применение

Country Status (17)

Country Link
US (1) US20210115143A1 (enExample)
EP (1) EP3612565A4 (enExample)
JP (2) JP2020517239A (enExample)
KR (1) KR102323960B1 (enExample)
CN (1) CN110856446A (enExample)
AU (1) AU2018256392B2 (enExample)
BR (1) BR112019021828B1 (enExample)
CA (1) CA3059447A1 (enExample)
CL (1) CL2019002953A1 (enExample)
CO (1) CO2019012118A2 (enExample)
EA (1) EA201900443A1 (enExample)
MA (1) MA50038A (enExample)
MX (1) MX2019012461A (enExample)
MY (1) MY199319A (enExample)
PH (1) PH12019502302A1 (enExample)
SG (1) SG11201909041SA (enExample)
WO (1) WO2018195226A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US11046769B2 (en) * 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
JP7619941B2 (ja) 2018-11-14 2025-01-22 アイバイオ， インク． Ｃｄ２５抗体
CN113646330A (zh) * 2018-11-14 2021-11-12 鲁比克治疗股份有限公司 工程化cd25多肽及其用途
CN109929037B (zh) * 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
US12331120B2 (en) 2019-04-11 2025-06-17 Scripps Korea Antibody Institute Antibodies against programmed death-ligand 1 and uses thereof
AU2020261961B2 (en) * 2019-04-26 2022-07-07 I-Mab Biopharma Co., Ltd. Human PD-L1 antibodies
US20210403568A1 (en) * 2020-06-29 2021-12-30 Cai Gu Huang Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation
WO2022031695A1 (en) * 2020-08-04 2022-02-10 Exelixis, Inc. Pd-l1 binding agents and uses thereof
TW202317640A (zh) * 2021-09-24 2023-05-01 大陸商廣東菲鵬製藥股份有限公司 一種抗人pd-l1人源化抗體或其抗原結合片段及其應用
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2454587C (en) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
TWI729512B (zh) * 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
AU2014339900B2 (en) * 2013-10-25 2019-10-24 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
CA2935375C (en) * 2014-01-06 2023-08-08 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
WO2015127288A1 (en) * 2014-02-20 2015-08-27 Alder Biopharmaceuticals, Inc. Anti-acth antibodies and use thereof
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
WO2016149201A2 (en) * 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
WO2018080812A1 (en) * 2016-10-30 2018-05-03 Henlix, Inc. Anti-pd-l1 antibodies and variants

Also Published As

Publication number Publication date
MA50038A (fr) 2020-07-08
SG11201909041SA (en) 2019-11-28
EP3612565A4 (en) 2021-06-16
WO2018195226A1 (en) 2018-10-25
KR20190141169A (ko) 2019-12-23
MY199319A (en) 2023-10-24
PH12019502302A1 (en) 2020-09-21
AU2018256392A1 (en) 2019-10-17
AU2018256392B2 (en) 2024-05-16
CA3059447A1 (en) 2018-10-25
CL2019002953A1 (es) 2020-01-10
MX2019012461A (es) 2019-12-11
CN110856446A (zh) 2020-02-28
JP2023025003A (ja) 2023-02-21
EP3612565A1 (en) 2020-02-26
JP2020517239A (ja) 2020-06-18
CO2019012118A2 (es) 2020-04-01
BR112019021828A2 (pt) 2020-03-24
BR112019021828B1 (pt) 2022-09-20
KR102323960B1 (ko) 2021-11-10
US20210115143A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
EA201900443A1 (ru) Антитело к pd-l1 и его применение
EA202092668A1 (ru) Антитела к ил-11
SA522431672B1 (ar) Cd3 أجسام مضادة للارتباط بـ
EA202193351A1 (ru) Связывающая молекула, специфическая в отношении cd73, и применение связывающей молекулы
EA201991214A1 (ru) Антитела против pd-1 и их композиции
MY189159A (en) Multispecific antigen-binding molecules and uses thereof
PH12020552229A1 (en) Il-11ra antibodies
MX2018016404A (es) Anticuerpos de union a cd3.
NZ704269A (en) Rspo3 binding agents and uses thereof
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
MX360543B (es) Anticuerpos st-2 humanos solubles y ensayos.
MX2022012083A (es) Moleculas de union de antigeno multiespecificas y usos de las mismas.
EA201791393A3 (ru) Антитела к erbb3 и их применение
MX2014000555A (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
EA201591762A1 (ru) Человеческие антитела к grem1
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
EA201991704A3 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
PH12019501089A1 (en) Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
EA202091974A1 (ru) Связывающие bcma антитела и их применение
WO2015112895A3 (en) Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
MX2022001947A (es) Anticuerpos que se unen a las proteinas lrp5 y metodos de uso.
BR112016023011A2 (pt) tratamento de câncer gástrico
EA201992136A1 (ru) Антитела против pd-l1
EA202191139A1 (ru) АНТИТЕЛА К EpCAM, АКТИВИРУЕМЫЕ АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И ИХ ПРИМЕНЕНИЕ
AR118522A1 (es) Moléculas de unión cd3